HLA-C and neoplasm: Unlike conventional TCRs, CARs recognize antigens independent of major histocompatibility complex (MHC) antigen presentation, avoiding the restriction of MHC molecules and solving the problem of tumor immune escape caused by the inhibition of MHC molecule expression [156, 157].